Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.
Launched by UCB PHARMA SA · Sep 6, 2005
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects with a confirmed diagnosis of epilepsy.
- • Subjects having experienced in the past unprovoked partial seizures (IA, IB, IC with clear focal origin),or generalized tonic-clonic seizures (without clear focal origin), that are classifiable according to the International Classification of Epileptic Seizures
- • Subjects having participated in the previous double-blind monotherapy trial (N01061 \[NCT00150735\] or N01093 \[NCT00150787\]).
- • Male/female subjects (\>= 16 years).
- Exclusion Criteria:
- • - Need for an additional Antiepileptic Drug (AED).
About Ucb Pharma Sa
UCB Pharma SA is a global biopharmaceutical company dedicated to the discovery and development of innovative therapies for patients with severe neurological and immunological disorders. With a strong commitment to scientific excellence, UCB focuses on addressing unmet medical needs through advanced research, strategic partnerships, and patient-centric approaches. Leveraging its expertise in biologics and small molecules, UCB aims to enhance the quality of life for individuals living with complex conditions, while fostering a culture of collaboration and integrity within the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lublin, , Poland
Szczecin, , Poland
Uppsala, , Sweden
Budapest, , Hungary
Warszawa, , Poland
Debrecen, , Hungary
Szeged, , Hungary
Katowice, , Poland
Göteborg, , Sweden
Brno, , Czechia
Karlstad, , Sweden
Beroun, , Czechia
Ceske Budejovice, , Czechia
Praha 1, , Czechia
Praha 5, , Czechia
Rychnov Nad Kneznou, , Czechia
Pécs, , Hungary
Białystok, , Poland
Gdańsk, , Poland
łódź, , Poland
Helsingborg, , Sweden
Huddinge, , Sweden
Patients applied
Trial Officials
UCB Cares
Study Director
001 844 599 2273 (UCB)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials